Equities

Tibet Rhodiola Pharmaceutical Holding Co

600211:SHH

Tibet Rhodiola Pharmaceutical Holding Co

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)31.82
  • Today's Change-0.36 / -1.12%
  • Shares traded1.35m
  • 1 Year change-18.36%
  • Beta2.8293
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,2021,7221,294
Total Receivables, Net903669727
Total Inventory111100137
Prepaid expenses141115
Other current assets, total1,1742118.00
Total current assets3,4032,7122,182
Property, plant & equipment, net602610793
Goodwill, net8.888.888.88
Intangibles, net204418456
Long term investments251271278
Note receivable - long term------
Other long term assets------
Total assets4,5874,1003,803
LIABILITIES
Accounts payable3942101
Accrued expenses937160
Notes payable/short-term debt500486534
Current portion long-term debt/capital leases0.881.002.13
Other current liabilities, total552426412
Total current liabilities1,1841,0261,110
Total long term debt1.131.141.86
Total debt502488538
Deferred income tax2.291416
Minority interest291915
Other liabilities, total262831
Total liabilities1,2431,0881,172
SHAREHOLDERS EQUITY
Common stock248248248
Additional paid-in capital1,2631,2661,265
Retained earnings (accumulated deficit)1,7731,4551,169
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total6143(51)
Total equity3,3453,0122,630
Total liabilities & shareholders' equity4,5874,1003,803
Total common shares outstanding248322322
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.